secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2026-08-12T11:31:19+00:00
Accession:  0001171843-26-005442
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Q2 net loss $5.1M; receives $178M Moderna payment, plans $230M buyback
------------------------------------------------------------------------------

- Q2 revenue fell to $1.0M from $10.7M YoY; net loss of $5.1M ($0.03/share) vs net income of $2.5M in 2025.
- Received $178.4M from Moderna settlement in July; owns ~16% of Genevant and expects a dividend.
- Board authorized up to $230M share repurchase program, may include tender offer, starting Q3 2026.
- Filed international patent lawsuits against Pfizer and BioNTech across 21 countries for LNP technology.
- FDA granted Fast Track for imdusiran; alignment on Phase 2b design for chronic hepatitis B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326005442/0001171843-26-005442-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326005442/f8k_081226.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-005442

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer